Again...made $$

Look at your formulary....they play in huge arena

Citigroup said it is upgrading Mylan (MYL) to a Buy rating as shares price reflects potential guidance cut and stock has bigger potential reward than TEVA.

All government programs and other insurances are increasing emphasis on generics

Mylan (MYL) was upgraded from Equal-weight to Overweight, Morgan Stanley said. $20 price target. Market is too pessimistic about growth, following the purchase of MRK's generic business.

Overblown worries about Merck aquisition. 2nd biggest generics...

Goldman Sachs upgraded Mylan (MYL) to Buy from Neutral. Sees bottom in shares, which are down 39% since announcement of Merck generics acquisition. Drivers include passing of overhang associated with acquisition, improved global positioning and competitive advantages coming from Merck generics, attractive three-year growth outlook, and defensive characteritics relative to slowing economic backdrop and election uncertainty. Pruice target at $19.

growing revenues low stock price

good industry - low p/e

Mylan (MYL) was upgraded from Market Perform to Outperform, Bernstein said. $18 price target. Company completed its financing and should enjoy favorable trends in the generic business.

poor price performance

poor management

On the downswing in the past six months, with low grades that suggest the stocks will be culled. Mylan Laboratories is down to 49.8

own